Bicara Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-55.4M | $-56.2M | $-37.4M | $-36.3M | $-27.4M | $-36.8M | $-21.0M | $-17.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $44.0K | $44.0K | $43.0K | $24.0K | $19.0K | $19.0K | $15.0K | $15.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $8.2M | $5.9M | $4.4M | $3.6M | $3.5M | $3.5M | $3.2M | $2.0M |
| Net Cash from Operating Activities | $-44.2M | $-37.5M | $-23.9M | $-29.2M | $-25.6M | $-28.1M | $-30.0M | $-17.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $60.0K | $60.0K | $238.0K | $42.0K | $0 | $0 | $40.0K | $8.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-185.0M | $100.9M | $-82.3M | $-236.1M | $0 | $0 | $-40.0K | $-8.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.3M | $163.3M | $31.2M | $436.0K | $135.0K | $460.0K | $-975.0K | $334.1M |
| Net Change in Cash | $-226.9M | $226.8M | $-75.0M | $-264.9M | $-25.5M | $-27.6M | $-31.0M | $316.9M |
| Free Cash Flow | $-44.3M | $-37.6M | $-24.1M | $-29.3M | $-25.6M | $-28.1M | $-30.1M | $-17.2M |